Shares of Verastem rose late Thursday after interim data from the company’s trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response rate.
Source link
Shares of Verastem rose late Thursday after interim data from the company’s trial evaluating a combination therapies to treat pancreatic cancer showed a high overall response rate.
Source link